Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab in Newly Diagnosed Multiple Myeloma (ElLen)
NCT06918002Phase 3Recruiting
- Start
- Jul 2025
- Primary completion
- May 2036
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of elranatamab in multiple myeloma (MM). Started Jul 2025; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06918002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06918002.